Effects of Pleuran (β-glucan from Pleurotus ostreatus) Supplementation on Incidence and Duration of Bronchiectasis Exacerbations

Jordan Minov; Sasho Stoleski; Jovanka Karadzinska-Bislimovska; Tatjana Petrova; Kristin Vasilevska; Dragan Mijakoski; Milos Jesenak

doi:10.3889/oamjms.2020.5266

Authors

Jordan Minov Department of Respiratory Functional Diagnostics, Institute for Occupational Health of Republic of Macedonia, Skopje – WHO Collaborating Center, Skopje, Republic of Macedonia
Sasho Stoleski Department of Respiratory Functional Diagnostics, Institute for Occupational Health of Republic of Macedonia, Skopje – WHO Collaborating Center, Skopje, Republic of Macedonia
Jovanka Karadzinska-Bislimovska Department of Respiratory Functional Diagnostics, Institute for Occupational Health of Republic of Macedonia, Skopje – WHO Collaborating Center, Skopje, Republic of Macedonia
Tatjana Petrova Department of Pharmacy Practice, Chicago State University, Chicago, USA
Kristin Vasilevska Department of Biostatistics, Institute for Epidemiology and Biostatistics, Skopje, Republic of Macedonia
Dragan Mijakoski Department of Respiratory Functional Diagnostics, Institute for Occupational Health of Republic of Macedonia, Skopje – WHO Collaborating Center, Skopje, Republic of Macedonia
Milos Jesenak Department of Paediatrics, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia

DOI:

https://doi.org/10.3889/oamjms.2020.5266

Keywords:

bronchiectasis, duration, exacerbation, incidence, pleuran

Abstract

BACKGROUND: Patients with non-cystic fibrosis bronchiectasis (BE) have frequent exacerbations that are causes of significant morbidity and sometimes mortality, and which it is desirable to prevent.

AIM: We aimed to assess the effects of pleuran on the incidence and duration of exacerbations in patients with BE.

METHODS: A prospective, observational, open-label, and active-controlled study was realized as a comparison of the frequency and duration of exacerbations between a group of patients with BE (30 patients, 14 males and 16 females, aged 44–72 years) who received a combination supplement containing pleuran 100 mg, Vitamin C 60 mg and zinc 5 mg over a 3-month period and a group of patients with BE (31 patients, 15 males and 16 females, aged 45–74 years) treated over a 3-month period with a combination supplement containing Vitamin C 60 mg and zinc 5 mg.

RESULTS: Over the study period, altogether 46 exacerbations were documented (19 in the patients receiving pleuran and 27 in the patients who did not receive pleuran), nine of which required hospital treatment (four in the patients receiving pleuran [21.5%] and five in the patients who did not receive pleuran [18.6%]). The mean number of exacerbations over the study period was significantly lower in the patients receiving pleuran (0.6 ± 0.4) as compared to the mean number in the patients who did not receive pleuran (0.8 ± 0.3) (p = 0.0297). The mean duration of exacerbations, expressed in days, needed for cure or clinical improvement in the patients receiving pleuran (11.2 ± 1.7 days) was significantly shorter than that of exacerbations in the patients who did not receive pleuran (12.4 ± 1.3 days) (p = 0.0029). We found significantly lower incidence and significantly shorter duration of exacerbations in the patients with BE who received pleuran as compared to their incidence and duration in the patients with BE who did not receive pleuran.

CONCLUSION: Our findings indicated a need for further investigations in this domain to define the possible role of pleuran in the prevention of BE exacerbations.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

King P, Holdsworth S, Freezer N, Holmes P. Bronchiectasis. Intern Med J. 2006;36(11):729-37. https://doi. org/10.1111/j.1445-5994.2006.01219.x PMid:17040360

Hill AT, Campbell AJ, Hill SL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med. 2000;109(4):288-93. https://doi.org/10.1016/ s0002-9343(00)00507-6 PMid:10996579

Redondo M, Keyt H, Dhar R, Chalmers JD. Global impact of bronchiectasis and cystic fibrosis. Breathe. 2016;12(3):223-35. https://doi.org/10.1183/20734735.007516 PMid:28210295

O’Donnel AF. Bronchiectasis. Chest. 2008;134(4):815-23. PMid:18842914

Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: A population-based cohort study. Eur Respir J. 2016;47(1):186-93. https://doi.org/10.1183/13993003.01033-2015 PMid:26541539

Boersma WG. Inhaled Antibiotics in Non-cystic Bronchiectasis: Better than Oral Antibiotics. Available from: http://www.ers-education.org/media/2016/pdf/298377.pdf. [Last accessed on 2018 Jul 20].

Pasteur MC, Bilton D, Hill AT. British Thoracic Society Bronchiectasis (non-CF) Guideline Group. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65(1):i1-58. https://doi.org/10.1136/thx.2010.136119 PMid:20627931

Hill TA, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, et al, EMBARC/BRR Definitions Working Group. Pulmonary exacerbation in adults with bronchiectasis: A consensus definition for clinical research. Eur Respir J. 2017;49(6):1700051. https:// doi.org/10.1183/13993003.00051-2017 PMid:28596426

Identifying an Exacerbation. Available from: https://www. bronchiectasis.com.au/bronchiectasis/management/identifying-an-exacerbation. [Last accessed on 2018 Jul 20].

Martinez-Garcia MA, Maiz L, Olveira C, Giron RM, de la Rosa D, Blanco M, et al. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults. Arch Bronconeumol. 2018;54(2):79-87. https://doi.org/10.1016/j.arbr.2017.07.013 PMid:29128130

Bronchiectasis Antibiotic Guidelines. Available from: https:// www.gloshospitals.nhs.uk. [Last accessed on 2018 Jul 20]. 12. Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature. 2001;413(6851):36-47. PMid:11544516

Goodridge HS, Wolf AJ, Underhill DM. Beta-glucan recognition by the innate immune system. Immunol Rev. 2009;230(1):38-50. PMid:19594628

Batbayar S, Lee DH, Kim HW. Immunomodulation of fungal β-glucan in host defense signaling by dectin-1. Biomol Ther. 2012;20(5):433-45. https://doi.org/10.4062/ biomolther.2012.20.5.433 PMid:24009832

Minov J, Karadzinska-Bislimovska J, Petrova T, Vasilevska K, Stoleski S, Mijakoski D. Effects of pleuran (B-glucan from Pleurotus ostreatus) supplementation on incidence and duration of COPD exacerbations. Open Access Maced J Med Sci. 2017;5(7):893-8. https://doi.org/10.3889/oamjms.2017.198 PMid:29362614

Spirometry Guide: 2010 Update. Available from: http://www. goldcopd.org/uploads/users/files/GOLD_Spirometry_2010. [Last accessed on 2017 16 Apr].

Barrow GI, Feltham RK. Cowan and Steel’s Manual for Identification of Medical Bacteria. 3rd ed. Cambridge, United Kingdom: Cambridge University Press; 2004.

Calculate Your Body Mass Index. Available from: https://www. nhlbi.nih.gov. [Last accessed on 2017 Apr 16].

World Health Organization. Guidelines for Controlling and Monitoring the Tobacco Epidemic. Geneva, Switzerland: World Health Organization; 1998.

Janson C, Chinn S, Jarvis D, Zock JP, Toren K, Burney P, European Community Respiratory Health Survey. Effects of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE in the European community respiratory health survey: A cross-sectional study. Lancet. 2001;358(9299):2103-9. https://doi.org/10.1016/ s0140-6736(01)07214-2 PMid:11784622

McGuinness G, Naidich DP. CT of airways disease and bronchiectasis. Radiol Clin North Am. 2002;40(1):1-19. PMid:11813813

Matsuoka S, Uchiyama K, Shima H, Ueno N, Oish S, Nojiri Y. Bronchoarterial ratio and bronchial wall thickness on high-resolution CT in asymptomatic subjects: Correlation with age and smoking. AJR Am J Roentgenol. 2003;180(2):513-8. https:// doi.org/10.2214/ajr.180.2.1800513 PMid:12540463

Smith IE, Jurriaans E, Diederich S, Ali N, Shneerson JM, Flower CD. Chronic sputum production: Correlation between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax. 1996;51(9):914-8. https://doi.org/10.1136/thx.51.9.914 PMid:8984702

Drain M, Elborn JS. Assessment and investigations in adult with bronchiectasis. Eur Respir Mon. 2011;52():32-43.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available from: https://www.goldcopd.org. [Last accessed on 2018 Jul 20].

Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576-85. https://doi.org/10.1164/ rccm.201309-1575oc PMid:24328736

Minov J, Karadzinska-Bislimovska J, Vasilevska K, Stoleski S, Mijakoski D. Assessment of the non-cystic bronchiectasis severity: The FACED score vs. The Bronchiectasis severity index. Open Respir Med J. 2015;9:46-51. https://doi. org/10.2174/1874306401509010046

Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, inflammatory indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(4):400-7. https:// doi.org/10.1164/rccm.200305-648oc PMid:15130905

Barker AF. Bronchiectasis. New Engl J Med. 2002;346(18):1383-93. PMid:11986413

King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Characterization of the onset and presenting clinical features of adult bronchiectasis. Respir. Med. 2006;100(12):2183-9. https:// doi.org/10.1016/j.rmed.2006.03.012 PMid:16650970

Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: Cellular and molecular mechanisms. Eur Respir J. 2008;31(2):396-406. https://doi. org/10.1183/09031936.00069007 PMid:18238949

Minov J, Karadzinska-Bislimovska J, Vasilevska K, Nelovska Z, Risteska-Kuc S, Stoleski S, et al. Smoking among Macedonian workers five years after anti-smoking campaign. Arh Hig Rada Toksikol. 2012;63:207-13. https://doi. org/10.2478/10004-1254-63-2012-2150

Minov J. Smoking Among Macedonian Workers. Saarbrücken, Germany: LAP LAMBERT Academic Publishing; 2013.

Cassone A, Bistoni F, Cenci E, Pesce CD, Tissi L, Marconi P. Immunopotentiation of anticancer therapy by Candida albicans, other yeasts and insoluble glucan in an experimental lymphoma model. Sabouraudia. 1982;20(2):115-25. https://doi. org/10.1080/00362178285380191Open Access Maced J Med Sci. 2020 Sep 15; 8(B):906-912. 911 PMid:7051368

Zhang Y, Xia L, Pang W, Wang T, Chen P, Zhu B, et al. A novel soluble β-1,3-D-glucan Salecan reduces adiposity and improve glucose tolerance in high-fat diet-fed mice. Br J Nutr. 2013;109(2):254-62. https://doi.org/10.1017/s0007114512000980 PMid:22716316

Haggard L, Andersson M, Punga AR. β-glucans reduce LDL cholesterol in patients with myasthenia gravis. Eur J Clin Nutr. 2013;67(2):226-7. https://doi.org/10.1038/ejcn.2012.191 PMid:23187951

Vannucci L, Krizan J, Sima P, Stakheev D, Caja F, Rajsiglova L, et al. Immunomodulatory properties and antitumor activities of glucans. Int J Oncol. 2013;43(2):357-64. https://doi.org/10.3892/ ijo.2013.1974 PMid:23739801

Jesenak M, Majtan J, Rennerova Z, Kyselovic J, BanovcinP, Hrubisko M. Immunomodulatory effect of pleuran (β-glucan from Pleurotus ostreatus) in children with recurrent respiratory tract infections. Int Immunopharmacol. 2013;15(2):395-9. https://doi.org/10.1016/j.intimp.2012.11.020 PMid:23261366

Grau JS, Sirvent LP, Ingles MM, Urgell MR. Beta-glucans from Pleurotus ostreatus for prevention of recurrent respiratory tract infections. Acta Pediatr Esp. 2015;73:186-93.

Bergendiova K, Tibenska E, Majtan J. Pleuran (β-glucan from Pleurotus ostreatus) supplementation, cellular immune response and respiratory tract infections in athletes. Eur J Appl Physiol. 2011;111(9):2033-40. https://doi.org/10.1007/ s00421-011-1837-z PMid:21249381

Bobovcak M, Kuniakova R, Gabriz J, Majtan J. Effect of pleuran (β-glucan from Pleurotus ostreatus) supplementation on cellular immune response after intensive exercise in elite athletes. Appl Physiol Nutr Metab. 2010;35(6):755-62. https://doi.org/10.1139/ h10-070 PMid:21164546